Cover Image
市場調查報告書

新一代抗體治療的全球市場預測 2016-2026年:ADC,改變抗體,ALP,及雙特異性/生技仿製藥抗體的主要企業的機會

Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents

出版商 Visiongain Ltd 商品編碼 261354
出版日期 內容資訊 英文 241 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
新一代抗體治療的全球市場預測 2016-2026年:ADC,改變抗體,ALP,及雙特異性/生技仿製藥抗體的主要企業的機會 Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents
出版日期: 2016年04月19日 內容資訊: 英文 241 Pages
簡介

全球新一代抗體市場收益預計2020年達到116億美元,到2026年有強力的收益成長。新的治療藥的市場進入,預計由於大型製藥企業投資,及慢性疾病治療的需求擴大到2026年拉抬銷售額。

本報告提供全球新一代抗體治療市場相關調查,銷售額資料,R&D趨勢,預測及機會分析等,今後的收益預測,整體市場及次市場的市場預測,主要企業與其市場佔有率,促進要素、阻礙要素等彙整資料,為您概述為以下內容。

第1章 調查概要

第2章 新一代抗體治療市場:簡介

  • 抗體:概要
  • 新一代抗體定義
  • 新一代抗體治療的分類
  • 新一代抗體技術的必要性
  • 新一代抗體的發展趨勢
  • 調查範圍
  • 臨床實驗的階段

第3章 新一代抗體治療:全球市場

  • 全球新一代抗體治療市場:概要及區分
  • 有代表性的新一代抗體治療
  • 全球新一代抗體治療市場:銷售額預測
  • 各種類的市場佔有率變化預測
  • 全球新一代抗體治療市場:促進要素、阻礙要素

第4章 主要的地區市場

  • 全球新一代抗體治療市場地區分析
  • 全球新一代抗體治療市場:各地區的預測
  • 各地區的市場佔有率變化預測
  • 美國的新一代抗體治療市場
  • 歐盟5國的新一代抗體治療市場
  • 亞太地區的新一代抗體治療市場
  • 南美的新一代抗體治療市場
  • 其他地區的新一代抗體治療市場

第5章 抗體藥複合體 (ADC) :市場預測、開發平台

  • 抗體藥複合體 (ADC) :市場概要
  • 主要的ADC
  • 抗體藥複合體 (ADC) :市場預測
  • 抗體藥複合體 (ADC) 市場:促進要素、阻礙要素
  • Adcetris (brentuximab vedotin, Seattle Genetics/武田藥品工業)
  • Kadcyla (trastuzumab emtansine, Roche)
  • Mylotarg (gemtuzumab ozogamicin, Pfizer)
  • 抗體藥複合體 (ADC) 平台
  • ADC富有魅力的高額契約
  • 抗體藥複合體 (ADC) :開發平台分析
  • 抗體藥複合體 (ADC) :第三階段開發平台
  • 抗體藥複合體 (ADC) :第二階段開發平台
  • 抗體藥複合體 (ADC) :第一階段開發平台
  • 抗體藥複合體 (ADC) :前臨床開發平台
  • ADC技術的未來發展

第6章 改變抗體:市場預測、開發平台

  • 改變抗體:定義
  • 市場概要及主要改變抗體
  • 改變抗體:市場預測
  • 改變抗體市場:促進要素、阻礙要素
  • Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
  • Gazyva/Gazyvaro (obinutuzumab, Roche)
  • 改變抗體的平台
  • 改變抗體:開發平台分析
  • 改變抗體:第三階段開發平台
  • 改變抗體:第二階段開發平台
  • 改變抗體:第一階段開發平台

第7章 雙特異性抗體市場:市場預測、開發平台

  • 雙特異性抗體:市場概要
  • 雙特異性抗體:市場預測
  • 雙特異性抗體市場:促進要素、阻礙要素
  • Removab (catumaxomab, Neopharm)
  • Blincyto (blinatumomab, Amgen)
  • 雙特異性抗體的平台
  • 雙特異性抗體:開發平台分析
  • 雙特異性抗體:第一階段、第1/2階段、前臨床開發平台

第8章 抗體片段、抗體樣蛋白質 (ALP) 市場預測、開發平台

  • 抗體片段、ALP:市場概要
  • 抗體片段、ALP:市場預測
  • 抗體片段、ALP:促進要素、阻礙要素
  • Kalbitor (ecallantide, Dyax)
  • 抗體片段、ALP的平台
  • 抗體片段、ALP:開發平台分析
  • 抗體片段、ALP:第二階段開發平台
  • 抗體片段、ALP:第一階段開發平台

第9章 生技仿製藥抗體:市場預測

  • 生技仿製藥抗體:市場概要
  • 主要的生技仿製藥抗體
  • 生技仿製藥抗體:市場預測
  • 生技仿製藥抗體市場:促進要素、阻礙要素

第10章 新一代抗體治療市場定性分析

  • 新一代抗體治療市場SWOT分析
  • 新一代抗體治療市場STEP分析
  • 新一代抗體開發主要的目標

第11章 調查採訪

第12章 結論

  • 新一代抗體治療市場高成長可能性
  • 市場及主要部門現況
  • 該報告刊載的主要新一代抗體治療
  • 主要市場
  • 今後的市場趨勢
  • 科技平台今後也將持續吸引市場很大的興趣
  • 開發商的大部分今後也將以癌症為標的
  • 成長策略

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0110

Next-Generation Antibody Therapies - Your 2016 Guide to Trends, R&D and Predicted Revenues

Where are next-generation antibody therapies heading? Visiongain's new report shows you potential revenues to 2026, giving R&D trends, opportunities and sales forecasting.

Discover in our study the most promising and lucrative parts of that industry. Our analysis lets you assess forecasted sales at overall world market, submarket, product and regional level. That work shows you results, interviews, trends and opportunities.

Many opportunities remain in that expanding market for new biological drugs. Discover what its future holds, with the following sections explaining how our study can help your work.

Forecasts from 2016-2026 and other analyses show you revenue potentials

Besides revenue forecasting to 2026, our new study shows you recent results, growth rates, and market shares. There you find original analyses exploring developments and business outlooks.

In our report you get 87 tables and 46 charts explaining that market. See what its future holds and the potential gains. Find data to benefit your plans, decisions and proposals.

There you also discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. You also find our interviews with three companies - Ablynx, arGEN-X and Mersana Therapeutics - giving insight to help you stay ahead.

Sales predictions for the world market and submarkets - see what is possible

Along with revenue prediction for the overall world market, our study shows you revenue forecasts to 2026 for the following five submarkets:

  • Antibody-drug conjugates (ADCs)
  • Engineered antibodies
  • Bispecific antibodies
  • Antibody fragments and antibody-like proteins (ALPs)
  • Biosimilar antibody therapies.

That investigation discusses what stimulates and restrains business. There discover what is possible for monoclonal antibodies and other agents. You find dynamics of the industry and assess its sales potentials, exploring treatments giving high commercial opportunities.

Leading next-generation therapeutic antibodies - what are their prospects?

How will leading next-generation antibody therapies perform to 2026 at world level? Our study forecasts individual revenues of seven products, showing you what revenues are possible:

  • Adcetris
  • Kadcyla
  • Gazyva/Gazyvaro
  • Poteligeo
  • Removab
  • Blincyto
  • Kalbitor.

image1

Discover how high those sales can go. With our study you see what is happening, exploring trends, challenges and opportunities.

Our analysis also breaks its main world forecast into geographical submarkets.

Leading regions - assess prospects for next-generation antibody sales

In addition to analyses of the overall world market, our study lets you explore individual revenue forecasts to 2026 for four regional markets:

  • US
  • EU5 group
  • Asia-Pacific region
  • Latin America
  • Rest of the World.

With that analysis you see where the highest and fastest expanding revenues can occur. That industry holds great potential for opportunities and rising sales. Discover what is possible.

Potential for market growth - how much expansion possible by 2020?

Our study predicts high revenue growth from 2016 to 2026. Launches of novel therapies, investments from international pharmaceutical companies and increasing demand for treatments for serious chronic diseases will increase those agents' sales from 2016 to 2026.

Our analysis forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. There discover capabilities, progress, and commercial prospects, helping you stay ahead in knowledge and benefit your reputation for commercial insight.

Research and development - assess innovation, trends and possibilities

What about R&D - the pipeline for new drugs? Our report explains, covering these fields:

  • Antibody-drug conjugates (ADCs)
  • Engineered antibodies
  • Bispecific antibodies
  • Antibody fragments and antibody-like proteins (ALPs)
  • Other progress in next-generation antibody development.

Our study also discusses these agents and technologies, among others:

  • Site-specific linkers
  • Glycosylation or glycoengineering
  • Defucosylation
  • Amino acid modification
  • Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC)
  • Bispecific, trispecific and multi-specific antibodies
  • Domain fragments
  • Single-chain variable fragments
  • Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies
  • Combination therapies.

R&D is particularly strong for antibody-drug conjugates. Also novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues to help your work.

Issues affecting the next-generation antibody therapies industry from 2016

Our survey discusses forces affecting those companies. There you find discussions of these and other issues:

  • Approved products indicating a path to regulatory and market acceptance
  • R&D for next generation antibodies - explore technologies and potentials
  • Challenges with current monoclonal antibody (mAb) therapies
  • Big pharma companies investing in next-generation antibody research and development
  • Biosimilars and their effects on the market for those next-generation biologics.

That investigation explains social, technological, economic and political forces, with emphasis on competition and business outlooks. Assess what drives and restrains developers, producers and marketers of those emerging biologic medicines.

7 ways Next-Generation Antibody Therapies Market Forecast 2016-2026 helps you

In these seven main ways, our new report helps your research, analysis, plans, decisions and presentations:

  • Revenue forecasts to 2026 for the world next-generation antibody therapies market and 5 segments - discover that industry's prospects, seeing its sales potentials
  • Predicted revenues to 2026 for the leading 4 regional markets - assess sales outlooks in the US, EU5, Asia-Pacific and Latin America
  • Sales potentials of 7 leading drugs to 2026 - see how high products' revenues can go
  • Review of R&D - investigate trends and progress, seeing what is possible, finding the most promising developments
  • Discussion of what stimulates and restrains leading companies - explore strengths, weaknesses, opportunities and threats, assessing that industry's prospects
  • Outlooks for established competitors and new market entrants - hear what scope exists for companies to increase their business and compete from 2016
  • Interviews from our survey, showing views from 3 companies - gain insight from that industry to help your work.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.

Trying our new study now lets you discover antibody trends, opportunities and forecasts

With our new report, by visiongain's UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of therapeutic antibodies. Find data you get nowhere else.

Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for new antibody-based drugs. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

Table of Contents

1. Report Overview

  • 1.1 Next-Generation Antibody Therapies Overview
  • 1.2 Global Next-Generation Antibody Therapies Market Segmentation
  • 1.3 Why you Should Read this Report
  • 1.4 How this Report Delivers
  • 1.5 Main Questions Answered by This Analytical Study
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Introduction to Next-Generation Antibody Therapies

  • 2.1 Antibodies: An Overview
    • 2.1.1 Monoclonal versus Polyclonal Antibodies
    • 2.1.2 A Brief History of Antibody Drug Development
    • 2.1.3 The Antibody Manufacturing Process
    • 2.1.4 Trends in Antibody Development
  • 2.2 Defining Next-Generation Antibodies
  • 2.3 Classification of Next-Generation Antibody Therapies
  • 2.4 The Need for Next-Generation Technologies
  • 2.5 Development Trends for Next-Generation Antibodies
  • 2.6 Scope of this Report
  • 2.7 Phases of Clinical Trials

3. Next-Generation Antibody Therapies: World Market 2016-2026

  • 3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
  • 3.2 Leading Next-Generation Antibody Therapies
  • 3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
  • 3.4 How Will Segmental Market Shares Change to 2026?
  • 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026

4. Leading Regional Markets 2016-2026

  • 4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
  • 4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
  • 4.3 How Will Regional Market Shares Change to 2026?
  • 4.4 US Next-Generation Antibody Therapies Market 2015-2026
  • 4.5 EU5 Next-Generation Antibody Therapies Market 2016-2026
  • 4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2026
  • 4.7 Latin American Next-Generation Antibody Therapies Market 2016-2026
  • 4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2026

5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2026

  • 5.1 Market Overview, 2016
  • 5.2 Leading ADCs in 2016
  • 5.3 Antibody-Drug Conjugates: Market Forecast 2016-2026
  • 5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2026
    • 5.4.1 Competition for Leading Drugs Will Restrain Growth
    • 5.4.2 Manufacturing ADCs Forms a Challenge
  • 5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
    • 5.5.1 Adcetris: Sales 2011-2015
    • 5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
    • 5.5.3 Expanding Adcetris Indications for Future Revenue Growth
    • 5.5.4 Adcetris Sales Forecast 2016-2026
  • 5.6 Kadcyla (trastuzumab emtansine, Roche)
    • 5.6.1 Mixed Results from Different Clinical Trials
    • 5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
    • 5.6.3 Kadcyla Sales Forecast 2016-2026
  • 5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
    • 5.7.1 Mylotarg to be Relaunched?
  • 5.8 Antibody-Drug Conjugate Platforms
    • 5.8.1 Limited Market Opportunity for Radioconjugation
    • 5.8.2 Seattle Genetics' Platform Accounted for Over 50% of the Pipeline in 2015
    • 5.8.3 ImmunoGen: TAP Technology
    • 5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
    • 5.8.5 Preclinical Platforms for ADC Development
  • 5.9 ADCs Have Attracted High-Value Deals and will Continue to do so
  • 5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2026
    • 5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
    • 5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
  • 5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
    • 5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
      • 5.11.1.1 Granted Breakthrough Therapy Designation
    • 5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
      • 5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
      • 5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
      • 5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
  • 5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
    • 5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
    • 5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
    • 5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
    • 5.12.4 Immunomedics' IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
    • 5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
    • 5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
    • 5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
    • 5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
    • 5.12.9 Seattle Genetics' Phase 1 and Phase 2 ADCs
      • 5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
      • 5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
      • 5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
      • 5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
  • 5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
  • 5.14 Antibody-Drug Conjugates: Preclinical Pipeline
  • 5.15 Future Developments in ADC Technology
    • 5.15.1 Site-Specific Linkage for Improved Safety Profiles

6. Engineered Antibodies: Market Forecast and Pipeline 2016-2026

  • 6.1 Defining an 'Engineered Antibody'
  • 6.2 Market Overview 2016, and the Leading Engineered Antibodies
  • 6.3 Leading Engineered Antibodies: Market Forecast 2016-2026
  • 6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2026
  • 6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
    • 6.5.1 Poteligeo Sales Forecast 2016-2026
  • 6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)
    • 6.6.1 Gazyva as a Challenger in the anti-CD20 Market
    • 6.6.2 Competition beyond Rituxan and Biosimilars
    • 6.6.3 Gazyva Receives Second Approval
    • 6.6.4 Gazyva Sales Forecast 2016-2026
  • 6.7 Engineered Antibodies Platforms
    • 6.7.1 Roche Glycart: GlucoMAb - Glycosylation for Improved ADCC
    • 6.7.2 Kyowa Hakko Kirin: Potelligent - Enhancing ADCC
    • 6.7.3 Glycotope: GlycoExpress
    • 6.7.4 MacroGenics: Fc Optimization
    • 6.7.5 Xencor: XmAb - Modifying Amino Acids in the Fc Domain
    • 6.7.6 Other Platforms for Increased Potency
  • 6.8 Engineered Antibodies: Pipeline Analysis 2016-2026
  • 6.9 Engineered Antibodies: Phase 3 Pipeline
    • 6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)
    • 6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
    • 6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
    • 6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
    • 6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
  • 6.10 Engineered Antibodies: Phase 2 Pipeline
    • 6.10.1 Glycotope's CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
    • 6.10.2 Margetuximab (anti-HER2, MacroGenics)
    • 6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
    • 6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
    • 6.10.5 Teplizumab (anti-CD3, MacroGenics)
    • 6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
    • 6.10.7 XmAb5871 (anti-CD19, Xencor)
  • 6.11 Engineered Antibodies: Phase 1 Pipeline

7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2026

  • 7.1 Bispecific Antibodies: Market Overview, 2016
  • 7.2 Bispecific Antibodies: Market Forecast 2016-2026
  • 7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2026
  • 7.4 Removab (catumaxomab, Neopharm)
    • 7.4.1 Removab: Sales Forecast 2016-2026
  • 7.5 Blincyto (blinatumomab, Amgen)
    • 7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
    • 7.5.2 Blincyto: Sales Forecast 2016-2026
  • 7.6 Bispecific Antibodies Platforms
    • 7.6.1 BiTE Platform: The Current Market Leader
    • 7.6.2 MacroGenics' DART Platform Holds Promise
    • 7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2026
    • 7.6.4 Other Bispecific Antibody Platforms
    • 7.6.4.1 DuoBodies (Genmab)
    • 7.6.4.2 ImmTAC (Immunocore)
  • 7.7 Bispecific Antibodies: Pipeline Analysis 2015-2026
    • 7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
    • 7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
    • 7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
    • 7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
    • 7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
    • 7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)
    • 7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
  • 7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline

8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2026

  • 8.1 Antibody Fragments and ALPs: Market Overview, 2016
  • 8.2 Antibody Fragments and ALPs: Market Forecast 2015-2026
  • 8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2026
  • 8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
    • 8.4.1 Kalbitor: Sales Forecast 2016-2026
  • 8.5 Antibody Fragments and ALPs Platforms
    • 8.5.1 Single-chain Variable Fragment Platforms
      • 8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
      • 8.5.1.2 Nanobodies: The Smallest Antibody Fragment
      • 8.5.1.3 Ablynx's Nanobody Platform Has Created Many Clinical Candidates
      • 8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
    • 8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
      • 8.5.2.1 DARPins: One-Tenth the Size of Antibodies
      • 8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
      • 8.5.2.3 Affibodies (Affibody)
      • 8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
      • 8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
      • 8.5.2.6 Adnectins (Bristol-Myers Squibb)
      • 8.5.2.7 AdAlta: i-bodies
    • 8.5.3 Which Platform Will Lead the Market 2016-2026?
  • 8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2026
    • 8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects
  • 8.7 Antibody Fragments and ALPs: Phase 3 Pipeline
    • 8.7.1 Caplacizumab (anti-vWF, Ablynx)
    • 8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
  • 8.8 Antibody Fragments and ALPs: Phase 2 Pipeline
    • 8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
    • 8.8.2 Ozoralizumab (anti-TNFα, Ablynx )
    • 8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
    • 8.8.4 ESBA1008 (anti-VEGF, Novartis)
  • 8.9 Antibody Fragments and ALPs: Phase 1 Pipeline
    • 8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
    • 8.9.2 ALX-0171 (anti-respiratory syncytial virus)
    • 8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
    • 8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline

9. Biosimilar Antibodies: Market Forecast 2016-2026

  • 9.1 Biosimilar Antibodies: Market Overview, 2016
  • 9.2 Leading Biosimilar Antibodies in 2016.
  • 9.3 Biosimilar Antibodies: Market Forecast 2016-2026
  • 9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2026
    • 9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
    • 9.4.2 Rising Incidence of Cancer will Drive Demand
    • 9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
    • 9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2026

  • 10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
    • 10.1.1 Strengths: The Path Towards Market Acceptance
    • 10.1.2 Weaknesses
      • 10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
    • 10.1.3 Opportunities
      • 10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
    • 10.1.4 Threats
      • 10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
  • 10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
    • 10.2.1 Social Factors: Rising Demand for Cancer Therapies
      • 10.2.1.1 Cancer Incidence Is Rising Rapidly
      • 10.2.1.2 Next-Generation Antibodies for Personalised Medicine
    • 10.2.2 Technological Developments Will Drive Pipeline Growth
      • 10.2.2.1 There Are Many Competing Platforms
      • 10.2.2.2 Manufacturing Challenges Exist for Most Sectors
      • 10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
    • 10.2.3 Economic Pressures
      • 10.2.3.1 Next-Generation Antibodies Are High-Cost
      • 10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
      • 10.2.3.3 Next-Generation Launches for Product Lifecycle Management
    • 10.2.4 Political and Regulatory Issues
      • 10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
  • 10.3 Key Targets for Next-Generation Antibody Development 2016-2026
    • 10.3.1 Oncology Is the Lead Indication in All Sectors
      • 10.3.1.1 HER2 and HER3 for Breast Cancer
      • 10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia

11. Research Interviews

  • 11.1 Interview with Dr Edwin Moses, CEO, Ablynx, Belgium
    • 11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
    • 11.1.2 Manufacturing Nanobodies
    • 11.1.3 Turning Challenges to Advantages
    • 11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
    • 11.1.5 The Commercial Potential for Nanobodies
    • 11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
  • 11.2 Interview with Tim van Hauwermeiren, CEO, arGEN-X, the Netherlands and Belgium
    • 11.2.1 arGEN-X's Development Pipeline
    • 11.2.2 Enhancing the Activity of ARGX-111
    • 11.2.3 arGEN-X's SIMPLE Antibody™ Platform
    • 11.2.4 Commercial Prospects for arGEN-X's Antibodies
    • 11.2.5 Plans for Growth
    • 11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
    • 11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
    • 11.2.8 Other Trends and Developments in the Market
  • 11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
    • 11.3.1 Mersana's Development Pipeline
    • 11.3.2 Advantages of the Fleximer Platform
    • 11.3.3 Future Plans for Mersana
    • 11.3.4 The Outlook for ADCs in 2015-2026

12. Conclusions

  • 12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2026
  • 12.2 Current Status of the Market and Leading Segments
  • 12.3 Leading Next-Generation Antibody Therapies Profiled in this Report
  • 12.4 Leading Regional Markets
  • 12.5 Development of the Market to 2026
  • 12.6 Technology Platforms Will Continue to Attract Big Pharma Interest
  • 12.7 Most Developers Continue to Target Cancer
  • 12.8 Strategies for Growth in 2016-2026

List of Figures

  • Figure 1.1 Global Next-Generation Antibody Therapies Market Segmentation Overview, 2016
  • Figure 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2015
  • Figure 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m) by Segment, 2015-2026
  • Figure 3.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2026
  • Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2016-2026
  • Figure 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) by Region, 2015
  • Figure 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2015-2026
  • Figure 4.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Region, 2026
  • Figure 4.4 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
  • Figure 4.5 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
  • Figure 4.6 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
  • Figure 4.7 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
  • Figure 4.8 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2015-2026
  • Figure 5.1 ADC Market Forecast: Revenues ($m), 2015-2026
  • Figure 5.2 ADC Market: Drivers and Restraints, 2016-2026
  • Figure 5.3 Seattle Genetics: Adcetris Revenue ($m), 2011-2015
  • Figure 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m), 2013-2015
  • Figure 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), 2015-2026
  • Figure 5.6 Kadcyla Revenue Forecast (Roche): Revenue ($m), 2015-2026
  • Figure 5.7 ADC Pipeline by Platform, 2015
  • Figure 5.8 ADC Pipeline by Phase, 2015
  • Figure 5.9 ADC Pipeline by Indication, 2015
  • Figure 6.1 Engineered Antibodies Market Forecast: Revenues ($m), 2015-2026
  • Figure 6.2 Engineered Antibodies Market: Drivers and Restraints, 2016-2026
  • Figure 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), 2015-2026
  • Figure 6.4 Total Gazyva Revenue Forecast (Roche): Revenue ($m), 2015-2026
  • Figure 6.5 Engineered Antibodies Pipeline by Company, 2015
  • Figure 6.6 Engineered Antibodies Pipeline by Indication, 2015
  • Figure 6.7 Engineered Antibodies Pipeline by Phase, 2015
  • Figure 7.1 Bispecific Antibodies Market: Drivers and Restraints, 2016-2026
  • Figure 7.2 Bispecific Antibodies Market Forecast: Revenue ($m), 2015-2026
  • Figure 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 7.4 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Figure 7.5 Bispecific Antibodies Pipeline by Company, 2015
  • Figure 7.6 Bispecific Antibodies Pipeline by Indication, 2015
  • Figure 7.7 Bispecific Antibodies Pipeline by Phase, 2015
  • Figure 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), 2015-2026
  • Figure 8.2 Antibody Fragments and ALPs Market: Drivers and Restraints, 2016-2026
  • Figure 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m), 2015-2026
  • Figure 8.4 Antibody Fragments and ALPs Pipeline by Company, 2015
  • Figure 8.5 Antibody Fragments and ALPs Pipeline by Indication, 2015
  • Figure 8.6 Antibody Fragments and ALPs Pipeline by Phase, 2015
  • Figure 9.1 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn), 2014-2026
  • Figure 9.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), 2014-2026
  • Figure 10.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2016-2026
  • Figure 10.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2016-2026

Companies Listed

  • AbbVie
  • Ablynx
  • AdAlta
  • ADC Therapeutics
  • Affimed Therapeutics
  • Agensys
  • Alcon
  • Alexion
  • Allergan
  • Ambrx
  • American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium
  • American Society of Hematology
  • Amgen
  • arGEN-X
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen Idec
  • BioNet Ventures
  • Biotest
  • BioWa
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cancer Drugs Fund
  • Catalent Pharma Solutions
  • Celgene
  • Celldex Therapeutics
  • Cephalon
  • Cilag GmbH International
  • Coldstream Laboratories
  • Concortis Biosystems
  • Corixa
  • Covagen
  • Crescendo Biologics
  • CSL Behring
  • CVie Therapeutics
  • Daiichi Sankyo
  • Defiante Farmaceutica
  • Delenex Therapeutics
  • Domantis
  • Dutalys
  • Dyax
  • Eddingpharm
  • Eisai
  • Eli Lilly
  • ESBATech
  • FDA
  • Five Prime Therapeutics
  • Fresenius Biotech
  • F-Star
  • Fujifilm
  • Genentech
  • Genmab
  • Gilead Sciences
  • Glenmark
  • Glycotope
  • Goodwin Biotechnology
  • GSK
  • Igenica
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • Janssen Biotech
  • Kalobios
  • Karolinska Institute
  • Kyowa Hakko Kirin
  • Kyowa Medex
  • LINDIS Biotech
  • Lonza
  • MacroGenics
  • MedImmune
  • Merck
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Micromet
  • Millennium Pharmaceuticals
  • Molecular Partners
  • MorphoSys
  • MultiCell Immunotherapeutics (MCIT)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Neopharm
  • Neovii Biotech
  • NHS
  • NICE
  • Novartis
  • Novartis Institutes for BioMedical Research (NIBR)
  • NovImmune
  • Oxford BioTherapeutics
  • Oxis
  • Pfizer
  • Pharmacyclics
  • Piarmal Healthcare
  • Pieris
  • Piramal Enterprises
  • PolyTherics
  • Progenics
  • ProStrakan
  • Redwood BioScience
  • Roche
  • Salix
  • Sanofi
  • Scil Proteins
  • Seattle Genetics
  • Servier
  • Shinogi
  • Shire
  • Sigma-Tau
  • Sorrento Therapeutics
  • Spectrum Pharmaceuticals
  • Spirogen
  • Stelis Biopharma
  • Strides Arcolab
  • Sutro Biopharma
  • Swedish Orphan Biovitrum (Sobi)
  • Swiss Federal Institute of Technology
  • Synthon
  • Takeda
  • Talon Therapeutics
  • Teva
  • TG Therapeutics
  • TRION Pharma
  • UCB
  • WHO
  • Wyeth
  • Xencor
  • Zydus Cadila
Back to Top